Viridian Therapeutics, Inc./DE
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-127.1M | $-104.9M | $-34.6M | $-100.7M | $-86.9M | $-76.7M | $-65.0M | $-48.5M |
| Depreciation & Amortization | — | $121.0K | — | — | $117.0K | — | — | $145.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $13.4M | — | — | $10.2M | — | — | $12.7M |
| Net Cash from Operating Activities | $-105.3M | $-119.7M | $-84.6M | $-75.4M | $-92.7M | $-67.7M | $-46.1M | $-45.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.3M | $23.0K | $127.0K | $42.0K | $86.0K | $293.0K | $104.0K | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $77.3M | — | — | $100.1M | — | — | $-143.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $6.4M | — | — | $9.2M | — | — | $177.1M |
| Net Change in Cash | — | $-36.0M | — | — | $16.6M | — | — | $-11.2M |
| Free Cash Flow | $-106.6M | $-119.7M | $-84.7M | $-75.4M | $-92.7M | $-68.0M | $-46.2M | $-45.2M |